RT Journal Article
SR Electronic
T1 COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by a quantitative and sensitive immunoassay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20064907
DO 10.1101/2020.04.17.20064907
A1 Ma, Huan
A1 Zeng, Weihong
A1 He, Hongliang
A1 Zhao, Dan
A1 Yang, Yunru
A1 Jiang, Dehua
A1 Zhou, Peigen
A1 Qi, Yingjie
A1 He, Weihuang
A1 Zhao, Changcheng
A1 Yi, Ruting
A1 Wang, Xiaofang
A1 Wang, Bo
A1 Xu, Yuanhong
A1 Yang, Yun
A1 Kombe, Arnaud John Kombe
A1 Ding, Chengchao
A1 Xie, Jiajia
A1 Gao, Yong
A1 Cheng, Linzhao
A1 Li, Yajuan
A1 Ma, Xiaoling
A1 Jin, Tengchuan
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.17.20064907.abstract
AB Background The current pandemic of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a great loss in lives and economy. Detecting viral RNAs on nasopharyngeal and throat swabs is the standard approach for SARS-CoV-2 diagnosis with variable success. Currently, there are only a few studies describing the serological diagnostic methods that involve the detection of SARS-CoV-2-specific IgM and IgG. Here, we aimed to develop a more quantitative and sensitive serological test for COVID-19 diagnosis, monitoring and clinical investigation, based on the detection of antigen-specific IgA as well as IgM and IgG in blood in response to SARS-CoV-2 infection.Methods In this investigation, we report the development of a set of validated diagnostic kits for detecting serum IgA, IgM, and IgG specific to SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein by chemi-luminescence immuno-analysis. The kits were tested with a cohort of 216 sera from 87 laboratory-confirmed COVID-19 patients, and 483 sera from SARS-CoV-2 negative or healthy individuals as negative controls. A standard receiver operating characteristic (ROC) analysis was conducted to evaluate the diagnostic accuracy. Using the kits, serum levels of IgA, IgM, and IgG were analyzed, in response to SARS-CoV-2 infection and COVID-19 pathogenesis.Findings The diagnostic kits based on the RBD antigen outperformed those based on the NP. RBD-specific IgA, IgM, and IgG detection kits showed sensitivities of 98·6%, 96·8%, and 96·8%, and specificities of 98·1%, 92·3%, and 99·8%, respectively. In addition, using purified RBD-specific immunoglobulins from a serum pool of COVID-19 patients as standards, the serum concentrations of RBD-specific IgA, IgM, and IgG proteins were determined. The concentrations varied widely among different patients. Median concentration of IgA and IgM reached peaks at 16-20 days after illness onset at 8·84 μg/mL and 7·25 μg/mL, respectively, while median concentration of IgG peaked during 21-25 days after illness onset at 16·47 μg/mL. Furthermore, the serum IgA level positively correlates with COVID-19 severity.Interpretation Our immunoassay of measuring SARS-CoV-2 specific antibodies IgA, IgM, and IgG in serum provides a better serological testing with improved sensitivity and specificity. Data of IgA, IgM, and IgG responses in blood of COVID-19 patients may provide novel insight for the monitoring and treatments of COVID-19. The kits are also suitable for epidemiological studies and vaccine validations.Funding Tengchuan Jin received funding from the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030104), a COVID-19 special task grant by Chinese Academy of Science Clinical Research Hospital (Hefei) with Grant No. YD2070002017. Huan Ma received a “new medical science” fund of USTC (WK2070000130).Evidence before this study On April 13th, 2020, we searched PubMed and preprint depositories with the key words COVID-19, SARS-CoV-2, antibody, IgM, IgG, or IgA. Ten studies described serum antibody responses in COVID-19 patients; most of them only measured IgM and IgG. Only three of them tested IgA levels. Relationship of serum IgA and disease severity has not been reported. The Lancet published an article on April 4th 2020, calling for “developing antibody tests for SARS-CoV-2”.Added value of this study We present serum profiles of IgA, IgM and IgG responses in a cohort of 87 COVID-19 patients. We found the RBD of the SARA-CoV-2 spike protein to be a better viral antigen than the nucleocapsid protein for diagnostic kits. IgA detection provides additional values for diagnosing and monitoring COVID-19. The combination of IgA/IgG or IgA/IgM/IgG provides improved diagnostic reliability as compared to conventional IgM/IgG combinations. In addition, we observed that IgA levels in serum correlate positively with COVID-19 severity.Implications of all the available evidence Highly sensitive and quantitative immunoassays to measure serum antibodies will improve clinical diagnosis and epidemiology study of COVID-19. It is of great interest that the serum IgA levels positively correlate with illness severity. Further studies on the role of IgA in disease progress are warranted.HighlightsDeveloped a highly quantitative and sensitive serologic immunoassay for SARS-CoV-2-specific IgA, IgM and IgG in COVID-19 patients.Showed the inclusion of IgA to the conventional IgM + IgG in a serological test improves the performance.Revealed the kinetics of three antibody isotypes in COVID-19 patients.Observed that serum IgA level positively correlated with COVID-19 disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTengchuan Jin received funding from the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030104), a COVID-19 special task grant by Chinese Academy of Science Clinical Research Hospital (Hefei) with Grant No. YD2070002017. Huan Ma received a “new medical science” fund of USTC (WK2070000130).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to our manuscript is available.